Facebook
Twitter
LinkedIn
Forward156 Renal Cell Carcinoma Multimodality Conference: (080122)
Dallas, TX US
August 1, 2022
To improve the care of patients with RCC. This Conference is focused primarily on the discussion of patient cases and periodically of clinical and basic research relevant to RCC
Target Audience
For physicians, PAs, RNs, researchers, medical and graduate students
Learning Objectives
The advancement of diagnosis and treatment of RCC through interdisciplinary expert discussions. After this conference, participants can explain and utilize information obtained for enhanced patient care
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX
75235
United States
Committee member(s)
James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
Jeffrey Cadeddu, MD
has a financial relationship (Stock Options) with Monarch Bioimplants;.
has a financial relationship (Stock) with Onconano;.
has a financial relationship (Stock Options) with Levita Magnetics;.
Hans Hammers, MD PhD
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Armo Biosciences;.
has a financial relationship (Independent contractor) with Surface Oncology;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Independent contractor) with Corvus;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Independent contractor) with BMS;.
Raquibul Hannan, MD, PhD, Associate Professor
has no relevant financial relationships to disclose at this time.
Course Director(s)
James Brugarolas, Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor, Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
has a financial relationship (Professional Services) with Consultant;.
Moderator(s)
Payal Kapur, MD
has no relevant financial relationships to disclose at this time.
Ivan Pedrosa, M.D., Ph.D.
has a financial relationship (Stock Options) with Health Tech International;.
has a financial relationship (Professional Services) with Merck;.
Speaker(s)
Todd Aguilera, M.D. Ph.D.
has a financial relationship (Intellectual Property Other) with UC San Diego;.
has a financial relationship (Grant Or Contract) with Galera Therapeutics;.
has a financial relationship (Stock) with Avelas Biosciences;.
has a financial relationship (Grant Or Contract) with iTeos;.
has a financial relationship (Intellectual Property Other) with Stanford University ;.
has a financial relationship (Grant Or Contract) with Apexigen Inc;.
Waddah Arafat
has a financial relationship (Professional Services) with DAVA Oncology;.
has a financial relationship (Professional Services) with Seagen;.
Suzanne Cole, MD
has no relevant financial relationships to disclose at this time.
Kevin Courtney, MD, PhD
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Patent) with Athena Diagnostics;.
has a financial relationship (Stock) with Regeneron Pharmaceuticals Inc;.
Jeffrey Howard
has no relevant financial relationships to disclose at this time.
Payal Kapur, MD
has no relevant financial relationships to disclose at this time.
Ivan Pedrosa, M.D., Ph.D.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Stock Options) with Health Tech International;.
Qian Qin, MD
has no relevant financial relationships to disclose at this time.
Available Credit
- 1.00 AMA
- 1.00 Attendance
Price
Cost:
$0.00
Please login or create an account to take this course.